2016 Archive:
ASX Announcements and News Releases

16/02/2016
Half Year Result 2016
CSL Delivers Exceptional Performance
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%.

16/02/2016
CSL Appoints New Director
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016.

29/02/2016
IDELVION® (rFIX-FP) - CHMP recommendation
CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B.

07/03/2016
IDELVION® (rFIX-FP) – FDA approval
CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring's novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B.

07/03/2016
Expanded Bio21 to house global research hub
The University of Melbourne's internationally recognized Bio21 Molecular Science and Biotechnology Institute is to be substantially expanded and will house CSL's Global Research and Translational Medicine Hub.

14/04/2016
CSL Announces $25 million Centenary Fellowship Program
CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia.

25/04/2016
CSL Celebrates 100 Years of Operation
Australia's largest and most successful biotechnology company, CSL, will officially celebrate 100 years of operation on 25th April 2016.

12/05/2016

IDELVION® (rFIX-FP) - European Commission Approval

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

24/05/2016

FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval

CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus' FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.

26/05/2016

AFSTYLA® (rFVIII-Single Chain) – FDA approval

CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring's novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.

01/06/2016

CSL Centenary Fellowships: Call for Applications

CSL is now calling for applications for the two inaugural fellowships to be awarded in late 2016, for commencement on 1 January 2017.

06/06/2016

Seqirus donates vaccines to Fiji to alleviate increase in influenza

CSL's subsidiary, Seqirus, today announced the donation of 20,000 doses of seasonal influenza vaccine to the people of Fiji in order to help alleviate a spike in cases of severe influenza.

10/06/2016

CSL Behring is 2016 'Victorian Manufacturer of the Year'

CSL Behring's Australian facility was last night awarded '2016 Victorian Manufacturer of the Year' in the Large Business category at the Victorian Manufacturing Hall of Fame Awards.

04/07/2016

CSL to Support new Biopharmaceutical Training Centre at UQ

CSL is pleased to announce it will be an inaugural partner of the new Australian Research Council Industrial Transformation Training Centre for Biopharmaceutical Innovation to be established at the University of Queensland.

17/08/2016

CSL Announces Changes to the Board

CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Dr Tadataka "Tachi" Yamada KBE has been appointed a Director effective from 1 September 2016. The Company also announced that Mr John Akehurst, has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company's Annual General Meeting on 12 October 2016.

17/08/2016

Full Year Result 2016

CSL Delivers Another Strong Performance

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016.

30/08/2016

FDA Accepts CSL Behring's BLA for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks

CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has accepted for review CSL Behring's Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks.

11/10/2016

Australian Scientists awarded $2.5m in support of ground-breaking research into Alzheimer's Disease and Leukaemia

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer's disease.

14/10/2016

New Debt Facilities

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 13 October 2016 it closed a new USD550 million private placement in the US. The private placement was foreshadowed in CSL's full year announcement in August 2016.

14/11/2016

AFSTYLA® (rFVIII-SC) - CHMP recommendation

CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for CSL Behring's AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.

01/12/2016

CSL Commits to New Phase I Clinical Trials in Australia

CSL has today announced that it has progressed three new therapies into first-in-human studies in Australia. In keeping with the Company's objective to expand its research and development pipeline and pursue a diverse portfolio, all three products are new generation, high-tech medicines based on targeted monoclonal antibody technologies.

22/12/2016

CSL CEO Says Holistic Approach To Business Is Essential To Corporate Sustainability, The Company's Value Chain And Patients

CSL Limited (ASX:CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its 2015/16 report the top 15 sustainability aspects important to its operations and stakeholders.